Philippines Business News API

{
    "totalArticles": 282850,
    "articles": [
        {
            "id": "7916fb5e24007f09fc2d1f73b9fd8c59",
            "title": "Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature",
            "description": "SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase 3 clinical studies of mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1, DREAMS-2) have been published back-to-back in Nature as Accelerated Article Previews (AAP) [DREAMS-1i,DREAMS-2ii].",
            "content": "SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of onc... [16626 chars]",
            "url": "https://www.manilatimes.net/2025/12/18/tmt-newswire/pr-newswire/nature-two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature/2245753",
            "image": "https://cdn4.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1920&q=100&f=webp&v=1",
            "publishedAt": "2025-12-18T00:16:26Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "7708fc8b4d29dfe2411310ae1101c80c",
            "title": "Grab reaffirms commitment to service accessibility amid holiday demand peak",
            "description": "Philippines has reiterated its commitment to keeping ride-hailing and food delivery services accessible this holiday season, banking on strategic partnerships and carpooling services like Grab Group Rides to mitigate the supply crunch driven by the sharp increase in demand.",
            "content": "MANILA, Philippines — Grab Philippines has reiterated its commitment to keeping ride-hailing and food delivery services accessible this holiday season, banking on strategic partnerships and carpooling services like Grab Group Rides to mitigate the su... [5315 chars]",
            "url": "https://www.philstar.com/the-freeman/metro-cebu/2025/12/18/2494438/grab-reaffirms-commitment-service-accessibility-amid-holiday-demand-peak",
            "image": "https://media.philstar.com/photos/2025/12/15/original-20e21917-5be9-4120-b5d6-ae9cc038057f_2025-12-15_11-10-35.jpg",
            "publishedAt": "2025-12-18T00:00:00Z",
            "lang": "en",
            "source": {
                "id": "762005c2c9a526818f8b84d930946662",
                "name": "Philstar.com",
                "url": "https://www.philstar.com"
            }
        },
        {
            "id": "414bc6282fd9e3d9901cdbae36348542",
            "title": "Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement",
            "description": "SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with the Nasdaq Stock Market (Nasdaq) continued listing standard for minimum share price under Rule 5450(a)(1) of the Nasdaq Listing Qualifications.",
            "content": "SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced i... [3902 chars]",
            "url": "https://www.manilatimes.net/2025/12/18/tmt-newswire/globenewswire/sutro-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement/2245694",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/18/872005.png",
            "publishedAt": "2025-12-17T21:17:21Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        }
    ]
}